<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337698</url>
  </required_header>
  <id_info>
    <org_study_id>BO39610</org_study_id>
    <secondary_id>2017-001267-21</secondary_id>
    <nct_id>NCT03337698</nct_id>
  </id_info>
  <brief_title>A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)</brief_title>
  <acronym>Morpheus Lung</acronym>
  <official_title>A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based&#xD;
      treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      Two cohorts will be enrolled in parallel in this study: the first-line (1L) cohort will&#xD;
      consist of patients who have not received any systemic therapy for their disease and the&#xD;
      second-line (2L) cohort will consist of patients who progressed during or after receiving a&#xD;
      platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor treatment. In each cohort,&#xD;
      eligible patients will be assigned to one of several treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">November 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Objective Response</measure>
    <time_frame>Every 6 weeks (starting on Day 1, Cycle 1) for the first 48 weeks and then every 6 or 12 weeks thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause (up to approximately 7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival After Randomization</measure>
    <time_frame>Randomization to death from any cause (up to approximately 7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Alive at Month 6 and at Month 12</measure>
    <time_frame>Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>First occurrence of a documented objective response to disease progression or death (up to approximately 7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause (up to approximately 7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline through the end of the study (approximately 7 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">435</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.&#xD;
Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.&#xD;
Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.&#xD;
Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + CPI-444</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Ipatasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.&#xD;
Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Evolocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab</arm_group_label>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + CPI-444</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Evolocumab</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Ipatasertib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy</arm_group_label>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Linagliptin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + Cobimetinib</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6958688</intervention_name>
    <description>Cycle 1:&#xD;
RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.&#xD;
Subsequent cycles:&#xD;
RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is administered by IV on Day 1 of each 21 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Docetaxel</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-444</intervention_name>
    <description>CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + CPI-444</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed is administered by IV on Day 1 of a 21 day cycle.</description>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.</description>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.</description>
    <arm_group_label>Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.</description>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.</description>
    <arm_group_label>Stage 1: Cohort 1: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
    <arm_group_label>Stage 2: Cohort 2: Atezolizumab + RO6958688</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Ipatasertib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is administered by IV on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacituzumab Govitecan</intervention_name>
    <description>Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Radiotherapy up to 21 days</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.</description>
    <arm_group_label>Stage 1: Cohort 2: Atezolizumab + Evolocumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1&#xD;
&#xD;
          -  Life expectancy greater than or equal to 3 months&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic, non-squamous or squamous&#xD;
             Non-Small Cell Lung Cancer (NSCLC)&#xD;
&#xD;
          -  Measurable disease (at least one target lesion)&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Tumor accessible for biopsy&#xD;
&#xD;
          -  Availability of peripheral blood for next-generation sequencing (NGS) circulating&#xD;
             tumor deoxyribonucleic acid (ctDNA) testing.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive measures and agreement to refrain from&#xD;
             donating eggs as outlined for each specific treatment arm&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures, and agreement to refrain from donating sperm, as outlined for&#xD;
             each specific treatment arm&#xD;
&#xD;
        Inclusion Criteria for Cohort 1&#xD;
&#xD;
          -  No prior systemic therapy for metastatic NSCLC&#xD;
&#xD;
          -  High tumor PD-L1 expression, defined as Tumor Proportion Score (TPS) &gt;= 50%&#xD;
&#xD;
        Inclusion Criteria for Cohort 2&#xD;
&#xD;
        - Disease progression during or following treatment for metastatic or locally advanced,&#xD;
        inoperable NSCLC&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently)&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)&#xD;
             metastases&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography scan&#xD;
&#xD;
          -  History of malignancy other than NSCLC within 2 years prior to screening&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO39610 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center; Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Mac Callum Cancer Center</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut De Cancerologie De L'Ouest; Medical Oncology</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44115</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center; Oncology</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4922297</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center; Oncology Dept</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)</name>
      <address>
        <city>Songpa-gu</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31620</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital; Gasterointestinal</name>
      <address>
        <city>Tainan City</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Cancer Institute</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

